Bicycle Therapeutics is a clinical-stage biopharmaceutical company founded in 2009 and headquartered in Cambridge, UK, with operations in Lexington, Massachusetts. The company is developing a proprietary class of therapeutics based on bicyclic peptides - short peptides constrained by small-molecule scaffolds into two stabilising loops - known as Bicycle® molecules.
Bicycle® molecules are designed to be fully synthetic, combining the high-affinity and selectivity properties associated with biologics with the pharmacokinetic and manufacturing advantages typical of small molecules. The company states that no immunogenicity has been observed to date in its programmes. The platform draws on Nobel Prize-winning science and is intended to address targets historically considered undruggable.
Bicycle Therapeutics is actively advancing multiple clinical programmes focused on solid tumour cancers, across two primary modalities:
- Bicycle Toxin Conjugates - Bicycle® molecules applied to deliver targeted toxin conjugates to solid tumours
- Bicycle Tumor-Targeted Immune Cell Agonists - Bicycle® molecules engineered to direct immune cell activation at the tumour site
Beyond oncology, the company's platform has applications across additional therapeutic areas including anti-infectives, cardiovascular disease, ophthalmology, and central nervous system disorders.
